Transgenic introduction of androgen receptor into estrogen-receptor-, progesterone-receptor-, and androgen-receptor-negative breast cancer cells renders them responsive to hormonal manipulation

Jennifer R. Garreau, Patrick Muller, Rodney Pommier, Su Ellen Johnson Pommier

    Research output: Contribution to journalArticle

    18 Citations (Scopus)

    Abstract

    Background: Estrogen-receptor (ER)-, progesterone-receptor (PR)-, and androgen-receptor (AR)-negative breast cancer cells are unaffected by treatment with dehydroepiandrosterone-sulfate (DHEAS) and an aromatase inhibitor (AI). We hypothesized that cell growth would be inhibited with DHEAS/AI treatment after successful transfection of an AR expression vector. Methods: ER/PR/AR-negative breast cancer cells were transfected with an AR expression vector and treated with DHEAS/AI for 2 days. Growth inhibition of these cells was compared with that of transfected cells treated with only AI or with nontransfected cells treated with DHEAS/AI. Mann-Whitney U test was used to determine statistical significance. Results: Cell death rates of 53.5% (P = .001) and 40.1% (P = .006) were seen in transfected cells treated with DHEAS/AI compared with controls for days 1 and 2, respectively. Nontransfected cells were unaffected by treatment. Comments: ER/PR/AR-negative cells transfected with AR were killed by DHEAS/AI treatment, providing evidence that AR is responsible for this effect. This provides the first AR-targeted hormonal therapy for ER breast cancer.

    Original languageEnglish (US)
    Pages (from-to)576-580
    Number of pages5
    JournalAmerican Journal of Surgery
    Volume191
    Issue number5
    DOIs
    StatePublished - May 2006

    Fingerprint

    Androgen Receptors
    Progesterone Receptors
    Aromatase Inhibitors
    Estrogen Receptors
    Dehydroepiandrosterone Sulfate
    Breast Neoplasms
    Growth
    Nonparametric Statistics
    Transfection
    Cell Death
    Mortality

    Keywords

    • Androgen receptor
    • Aromatase inhibitor
    • Breast cancer
    • Dehydroepiandrosterone-sulfate

    ASJC Scopus subject areas

    • Surgery

    Cite this

    @article{beac24438f81407ea029551f66e096c5,
    title = "Transgenic introduction of androgen receptor into estrogen-receptor-, progesterone-receptor-, and androgen-receptor-negative breast cancer cells renders them responsive to hormonal manipulation",
    abstract = "Background: Estrogen-receptor (ER)-, progesterone-receptor (PR)-, and androgen-receptor (AR)-negative breast cancer cells are unaffected by treatment with dehydroepiandrosterone-sulfate (DHEAS) and an aromatase inhibitor (AI). We hypothesized that cell growth would be inhibited with DHEAS/AI treatment after successful transfection of an AR expression vector. Methods: ER/PR/AR-negative breast cancer cells were transfected with an AR expression vector and treated with DHEAS/AI for 2 days. Growth inhibition of these cells was compared with that of transfected cells treated with only AI or with nontransfected cells treated with DHEAS/AI. Mann-Whitney U test was used to determine statistical significance. Results: Cell death rates of 53.5{\%} (P = .001) and 40.1{\%} (P = .006) were seen in transfected cells treated with DHEAS/AI compared with controls for days 1 and 2, respectively. Nontransfected cells were unaffected by treatment. Comments: ER/PR/AR-negative cells transfected with AR were killed by DHEAS/AI treatment, providing evidence that AR is responsible for this effect. This provides the first AR-targeted hormonal therapy for ER breast cancer.",
    keywords = "Androgen receptor, Aromatase inhibitor, Breast cancer, Dehydroepiandrosterone-sulfate",
    author = "Garreau, {Jennifer R.} and Patrick Muller and Rodney Pommier and Pommier, {Su Ellen Johnson}",
    year = "2006",
    month = "5",
    doi = "10.1016/j.amjsurg.2006.02.004",
    language = "English (US)",
    volume = "191",
    pages = "576--580",
    journal = "American Journal of Surgery",
    issn = "0002-9610",
    publisher = "Elsevier Inc.",
    number = "5",

    }

    TY - JOUR

    T1 - Transgenic introduction of androgen receptor into estrogen-receptor-, progesterone-receptor-, and androgen-receptor-negative breast cancer cells renders them responsive to hormonal manipulation

    AU - Garreau, Jennifer R.

    AU - Muller, Patrick

    AU - Pommier, Rodney

    AU - Pommier, Su Ellen Johnson

    PY - 2006/5

    Y1 - 2006/5

    N2 - Background: Estrogen-receptor (ER)-, progesterone-receptor (PR)-, and androgen-receptor (AR)-negative breast cancer cells are unaffected by treatment with dehydroepiandrosterone-sulfate (DHEAS) and an aromatase inhibitor (AI). We hypothesized that cell growth would be inhibited with DHEAS/AI treatment after successful transfection of an AR expression vector. Methods: ER/PR/AR-negative breast cancer cells were transfected with an AR expression vector and treated with DHEAS/AI for 2 days. Growth inhibition of these cells was compared with that of transfected cells treated with only AI or with nontransfected cells treated with DHEAS/AI. Mann-Whitney U test was used to determine statistical significance. Results: Cell death rates of 53.5% (P = .001) and 40.1% (P = .006) were seen in transfected cells treated with DHEAS/AI compared with controls for days 1 and 2, respectively. Nontransfected cells were unaffected by treatment. Comments: ER/PR/AR-negative cells transfected with AR were killed by DHEAS/AI treatment, providing evidence that AR is responsible for this effect. This provides the first AR-targeted hormonal therapy for ER breast cancer.

    AB - Background: Estrogen-receptor (ER)-, progesterone-receptor (PR)-, and androgen-receptor (AR)-negative breast cancer cells are unaffected by treatment with dehydroepiandrosterone-sulfate (DHEAS) and an aromatase inhibitor (AI). We hypothesized that cell growth would be inhibited with DHEAS/AI treatment after successful transfection of an AR expression vector. Methods: ER/PR/AR-negative breast cancer cells were transfected with an AR expression vector and treated with DHEAS/AI for 2 days. Growth inhibition of these cells was compared with that of transfected cells treated with only AI or with nontransfected cells treated with DHEAS/AI. Mann-Whitney U test was used to determine statistical significance. Results: Cell death rates of 53.5% (P = .001) and 40.1% (P = .006) were seen in transfected cells treated with DHEAS/AI compared with controls for days 1 and 2, respectively. Nontransfected cells were unaffected by treatment. Comments: ER/PR/AR-negative cells transfected with AR were killed by DHEAS/AI treatment, providing evidence that AR is responsible for this effect. This provides the first AR-targeted hormonal therapy for ER breast cancer.

    KW - Androgen receptor

    KW - Aromatase inhibitor

    KW - Breast cancer

    KW - Dehydroepiandrosterone-sulfate

    UR - http://www.scopus.com/inward/record.url?scp=33744493428&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=33744493428&partnerID=8YFLogxK

    U2 - 10.1016/j.amjsurg.2006.02.004

    DO - 10.1016/j.amjsurg.2006.02.004

    M3 - Article

    VL - 191

    SP - 576

    EP - 580

    JO - American Journal of Surgery

    JF - American Journal of Surgery

    SN - 0002-9610

    IS - 5

    ER -